

Technology Advisory Committee C Interests Register

Topic: Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID6302]

Publication Date: 11/09/2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Satish Venkateshan	TAC C Committee member	Financial interest	Regeneron is developing therapeutics for a broad range of diseases including solid tumours. Satish Venkateshan works for Regeneron, pharmaceuticals/biotech company. Satish also owns shares in the company and has stock options.	12/06/2024	It was agreed that Satish Venkateshan's declaration would prevent him from participating in discussions on this appraisal.
Professor John Bridgewater	Clinical expert	Direct-financial interest Direct-non-financial interest	Professor John Bridgewater has participated in advisory boards for both futibatinib and pemigatinib. and has had speaker fees from the competitor, Incyte. All these total approximately £5000. The University of Birmingham has received research funding from the competitor organisation, Incyte. This is in the region of £500000.	02/07/2024	It was agreed that Professor John Bridgewater's declaration would not prevent him from providing expert advice to the committee.

